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Therefore, we investigated the effect of radiotherapy on 
Ledderhose disease. 
 
Material and Methods: Between 2008 and 2014, 37 patients 
(56 feet) with Ledderhose disease were treated with 
radiotherapy at our department (figure 1). Radiation 
treatment consisted of 30 Gy given in 10 fractions (orthovolt 
200 kV or electrons 6-10 MeV). After the first 5 fractions, a 8-
10 week split was included. After this split, the remaining 5 
fractions were given. Progressive disease (PD) was defined as 
progression of complaints. Stable disease (SD) was defined as 
no improvement or progression of complaints. Partial 
response (PR) was defined as improvement or no complaints, 
but still nodules were present. Complete response (CR)was 
defined as no complaints and no nodules present. 
 
Results: All patients completed the planned treatment. The 
mean follow-up time was 25 months (range 3 to 46 months). 
Mean age of patients was 53 years, 46% were men, 54% were 
women. In 51% of patients (n=19), both feet were affected. 
After the radiotherapy, a minority of the patients complained 
of rash or dry skin, which resolved spontaneously. Of the 56 
feet treated, 5% had PD, 23% had SD, 64% had PR and 7% had 
CR. No radiation induced malignancies were seen. Of the two 
patients with PD, one patient had previous surgery for 
Ledderhose disease and the other patient had PD disease 
after an initial PR. 
 
 
Conclusion: Radiotherapy is an effective treatment for 
Ledderhose disease. However, the National Health Care 
Institute of the Netherlands does not support radiotherapy 
for Ledderhose disease as no randomized controlled trail 
have investigated the efficacy of radiotherapy. Therefore, we 
will present a double blind randomized multicentre phase 
three study to confirm the current results prospectively. 
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Purpose or Objective: Nowadays stereotactic body 
radiotherapy (SBRT) is considered a safe and effective 
approach for several sites of metastatic disease. So far, few 
published data exist on local control rates of radiotherapy in 
the context of isolated or limited lymph node metastases. We 
analyzed the dosimetric and clinical results of 
oligometastatic patients treated with SBRT for isolated lymph 
node metastases in abdomen and/or pelvis. 
 
Material and Methods: In the analysis we included patients 
with a maximum of 3 lymph node sites of disease with 
diameter less than 5 cm, located in the abdomen or pelvis. 
Radiotherapy was administered with Volumetric Modulated 
Arc Therapy Rapid-Arc (VMAT-RA) and flattening filter-free 
(FFF) beams; prescribed dose was 45 Gy in 6 fractions of 7.5 
Gy each. We analyzed dosimetric data and correlated them 
with acute toxicity (CTCAE 3.0), local and distant control of 
disease, progression free survival and overall survival. 
 
Results: From January 2006 to May 2015, we treated 97 
patients with lymph node metastases, of which 26 were lost 
at follow-up. We analyzed then 71 patients with a total of 79 
treated lesions, with a mean follow-up of 1.44 years (range 
0.14 – 6.21 years). At revaluation, complete response was 
achieved in 39 (49.3%) lesions and partial response in 28 
(35.4%) lesions. Stable disease was demonstrated in 10 
(12.6%) cases while only 2 (2.5%) lesions showed progression 
of disease. The overall clinical benefit rate was 97.5% (77/79 
lesions). Acute toxicity was mild: 10 (14%) patients reported 
G1 toxicity (notably nausea and fatigue); 2 (2.8%) patients 
reported G2 toxicity (nausea and diarrhea). No Grade 3 and 4 
toxicities were reported. In-field progression of disease 
during follow-up was demonstrated in 18 sites (22.7%) with a 
median time of 10.7 months. Out-field lymph node 
progression was demonstrated in 22 (27.8%) cases while 
distant metastases occurred in 25 (31.6%) cases. Local control 
rate and overall survival rate at 1 year were 83% and 93%, 
respectively. 
 
Conclusion: In consideration of our dosimetric and clinical 
results, SBRT with VMAT-RA and FFF beams can be considered 
a safe and effective approach in oligometastatic patients 
with abdomino-pelvic isolated lymph node metastases. 
Although this can be considered an initial experience, these 
results may be potentially significant for preserving quality of 
life of patients and delaying further systemic treatments. 
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Purpose or Objective: The purpose of this study was to 
evaluate the efficacy and feasibility of carbon ion 
